| American Cancer Society’s Cancer Facts & Figures 2022, released today, reports that the five-year survival rate for pancreatic cancer has increased to 11%. This one percentage point increase over last year signifies important progress, says Julie Fleshman, JD, MBA, PanCAN’s president and CEO, as it represents 622 more loved ones who will make it to five years after their pancreatic cancer diagnosis. Still, much work remains to be done. “A five-year survival rate of 11%, and the increase of five percentage points over the last decade, tell us that our efforts are working,” she says. “PanCAN’s initiatives are more important than ever to improve outcomes for pancreatic cancer patients.”  Julie Fleshman, JD, MBA, PanCAN’s President and CEO, speaks out about the five-year survival rate for pancreatic cancer increasing to 11% in 2022 in this short video. PanCAN’s Know Your Tumor® precision medicine service is one example of a program making a difference. Launched in 2014, the service matches patients with treatment options tailored to their tumor’s biology. PanCAN is also working to improve survival rates through initiatives like PanCAN Precision PromiseSM, a clinical trial designed to accelerate new treatment options, and PanCAN’s Early Detection Initiative, aiming to find an early detection strategy for the disease. “Our large-scale research initiatives, like Precision Promise and our Early Detection Initiative, continue to spark discoveries,” says Fleshman. “They’re at the leading edge of the next decade of progress in the fight against pancreatic cancer.” Donors make all of PanCAN’s initiatives possible. Thanks to our tremendous donors, the five-year survival is increasing. Over the next decade, we look forward to more opportunities to accelerate the pace of progress with your continued support. Donate today to advance leading-edge research that continues to help pancreatic cancer patients live longer. |